Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

119
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
119
Cancer Therapies02:49

Cancer Therapies

9.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

121
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of heart failure after hospitalization].

Revue medicale suisse·2025
Same author

Evaluation of Aktiia cuffless blood pressure monitor across 24-h, daytime, and night-time measurements versus ambulatory monitoring: a prospective, single-centre observational study.

Journal of hypertension·2025
Same author

[Cardiology: what's new in 2023].

Revue medicale suisse·2024
Same author

Platypnea-Orthodeoxia Syndrome Associated With Large Right Ventricular Fibroelastoma Successfully Treated by Transcatheter Approach: A Case Report.

CJC open·2023
Same author

The future of blood pressure monitoring: what's next?

Hypertension research : official journal of the Japanese Society of Hypertension·2023
Same author

Arrhythmias and Clinical Outcomes in a Swiss Multicenter Cohort of Patients With Dextro-Transposition of the Great Arteries and Atrial Switch.

Journal of the American Heart Association·2023
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.9K

[Cardio-oncology : a specialty for the future].

Stefania Aur1,2, Sabina Rosset1, Patrick Monnier1

  • 1Service de cardiologie, Département de médecine, Réseau hospitalier neuchâtelois, 2000 Neuchâtel.

Revue Medicale Suisse
|March 3, 2021
PubMed
Summary
This summary is machine-generated.

Cardio-oncology advances cancer patient survival but introduces cardiac toxicities. This specialty aims to balance effective cancer treatment with heart protection, preventing and managing side effects from cardiotoxic drugs.

More Related Videos

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.3K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.1K

Related Experiment Videos

Last Updated: Nov 15, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.9K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.3K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.1K

Area of Science:

  • Cardio-oncology
  • Cardiovascular Medicine
  • Oncology

Background:

  • Cancer therapies have significantly improved patient survival rates over the past decade.
  • These modern treatments often introduce a range of cardiac toxicities, impacting cardiovascular health.
  • Cardiotoxicity can lead to severe and adverse patient outcomes.

Purpose of the Study:

  • To optimize oncological treatment delivery while safeguarding the heart and vascular system.
  • To establish a dedicated cardio-oncology unit focused on patient care.
  • To prevent, treat, and monitor patients experiencing cardiotoxicity from cancer drugs.

Main Methods:

  • Multidisciplinary approach integrating oncology and cardiology expertise.
  • Proactive cardiac risk assessment for patients undergoing cancer therapy.
  • Implementation of surveillance protocols for cardiotoxicity detection.

Main Results:

  • Identification of key cardiac toxicities associated with novel cancer treatments.
  • Development of strategies to mitigate cardiovascular adverse events.
  • Improved management protocols for patients at risk of cardiotoxicity.

Conclusions:

  • Cardio-oncology is crucial for managing the cardiovascular complications of cancer therapy.
  • Integrated care models enhance patient survival and quality of life.
  • Early detection and intervention are vital for managing cardiotoxicity.